J&J Topamax Glaucoma Warning, Lennox-Gastaut Indication Added To Label
Executive Summary
Johnson & Johnson's Topamax (topiramate) acute myopia and secondary angle glaucoma label warnings will be the subject of a "Dear Healthcare Professional" letter.
You may also be interested in...
Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
Centocor's efforts to increase tuberculosis screening prior to Remicade therapy are working as intended, Johnson & Johnson VP-Investor Relations Helen Short told an Oct. 16 earnings call.
Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
Centocor's efforts to increase tuberculosis screening prior to Remicade therapy are working as intended, Johnson & Johnson VP-Investor Relations Helen Short told an Oct. 16 earnings call.
J&J Topamax Expansion Will Include Lennox-Gastaut; "Approvable" At FDA
Johnson & Johnson's first step in expanding the Topamax label within the seizure market could be for a Lennox-Gastaut syndrome indication, Group Chairman Joseph Scodari suggested during an analyst R&D day in La Jolla, Calif. May 30.